Navigation Links
Red blood cell hormone modulates the immune system
Date:1/20/2011

New research reveals that a hormone best known for stimulating the production of red blood cells can modulate the immune response. The study, published by Cell Press in the January 27th issue of the journal Immunity, finds that erythropoietin (EPO) has contrasting influences on infectious and inflammatory diseases and may be useful in the design of new therapeutic strategies.

EPO is a cytokine hormone that stimulates the production of red blood cells by acting at EPO receptors (EPORs) on red blood cell precursors. Interestingly, other cell types also express EPORs. "It is clear that EPORs are present on immune cells, but the function of these receptors was completely unknown," says senior study author Dr. Guenter Weiss from Innsbruck Medical University in Austria. "We hypothesized that EPO might be able to modulate the immune system and could be of clinical relevance in certain diseases."

After showing that EPO inhibited induction of key pro-inflammatory genes, Dr. Weiss and colleagues examined the role of EPO-modulated immune cells in two mouse models of disease: systemic infection with Salmonella bacteria and chemically induced inflammation of the colon (colitis).

In mice infected with Salmonella, EPO treatment was associated with reduced survival and impaired ability to clear the pathogen, neutralization of EPO production in the body promoted Salmonella elimination. This suggests that EPO reduces the ability of the immune system to fight off a systemic infection with intracellular bacteria such as Salmonella.

The researchers went on to show that in contrast to bacterial infection, EPO had a beneficial effect on the severity of colitis. EPO decreased the production of nuclear factor (NF)-B, a protein that is critical for inflammation and thereby reduced the formation of cytokines such as tumor necrosis factor alpha which are centrally involved in the pathogenesis of autoimmune colitis. This suggests that EPO may exert beneficial effects in non-infectious inflammatory diseases.

"Our results provide novel evidence that EPO acts as a potent anti-inflammatory immune modulator by specifically targeting (NF)-B-driven inflammatory pathways," concludes Manfred Nairz, first author of the paper. "Although high dose EPO treatment in humans may lead to a dangerous excess of red blood cells, EPO derivatives that do not influence red blood cell production have been developed and these could possibly serve as valuable therapeutic tools in treatment of pathologic inflammation."


'/>"/>

Contact: Elisabeth Lyons
elyons@cell.com
617-386-2121
Cell Press
Source:Eurekalert

Related biology news :

1. Scientist plans to test for blood pressure genes affected by age
2. Discovery of natural compounds that could slow blood vessel growth
3. New blood test for Down syndrome
4. On the trail of a targeted therapy for blood cancers
5. Lower your blood pressure, hydrate your skin and reduce dental plaque -- with chocolate?
6. Building the blood-brain barrier
7. Apelin hormone injections powerfully lower blood sugar
8. Battling bacteria in the blood: Researchers tackle deadly infections
9. Femtomolar optical tweezers may enable sensitive blood tests
10. Drops in blood oxygen levels may be key to sudden death in some epilepsy patients
11. Scripps research scientists identify blood component that turns bacteria virulent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2016)... , March 31, 2016   ... ("LegacyXChange" or the "Company") LegacyXChange is excited ... of its soon to be launched online site for ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders a ... DNA technology to an industry that is notorious for ...
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
(Date:3/22/2016)... 22, 2016 According ... Market for Consumer Industry by Type (Image, Motion, ... (Communication & IT, Entertainment, Home Appliances, & ... to 2022", published by MarketsandMarkets, the market ... reach USD 26.76 Billion by 2022, at ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... -- A person commits a crime, and the detective uses ... criminal down. An outbreak of foodborne illness makes ... uses DNA evidence to track down the bacteria that caused ... not. The FDA has increasingly used a complex, cutting-edge technology ... Put as simply as possible, whole genome sequencing is a ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
Breaking Biology Technology: